Page 2 - Patrick Barth News Today

New data demonstrate ENSPRYNG’s robust and sustained longer-term efficacy in preventing relapses in people with neuromyelitis optica spectrum disorder...

New data demonstrate ENSPRYNG's robust and sustained longer-term efficacy in preventing relapses in people with neuromyelitis optica spectrum disorder (NMOSD) More than 70% of people treated with

Investegate announcements from F. Hoffmann-La Roche Ltd, [Ad hoc announcement pursuant to Art. 53 LR] Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD)Gantenerumab is the first and only anti-amyloid antibody being investigated for subcutaneous administration

Trial met primary endpoint, showing Ronapreve significantly reduced viral load in seronegative patients hospitalised with COVID-19 who did not require high-flow oxygen or mechanical ventilation at baselineClinical

Acute respiratory infections are one of the leading causes of death and disability globally, presenting substantial health challenges especially for infants, the elderly and the immunocompromised.1-3Three

F. Hoffmann-La Roche Ltd: FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes need for new treatment options 1 Ib This is the 11th Breakthrough Therapy Designation for Roches haematology Venclexta demonstrating its potential across multiple blood cancers Basel, 21 July 2021 - Roche] study is a phase Ib, open-label, non-randomised, multicentre, dose-finding study evaluating Venclexta/Venclyxto (...

F. Hoffmann-La Roche Ltd: Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 casirivimab hospitalised patients Basel, 20 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japans Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve(casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. The antibody combination was granted a Specia...

) Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins involved in the natural coagulation cascade, and restore the blood clotting process for people with haemophilia A. Hemlibra is a prophylactic (preventative) treatment that can be administered by an injection of a ready-to-use solution under the skin (subcutaneously) once-weekly, every two weeks or every four weeks (after an initial once-weekly dose for the fi...

F. Hoffmann-La Roche Ltd: New data for Roches Hemlibra reinforce safety profile in people with haemophilia A IIIb haemophilia Hemlibra 1 STASEY is one of the largest open-label studies primarily assessing safety and tolerability of a medicine for people with haemophilia Hemlibra also continued to demonstrate effective bleed control with a high proportion of participants (82.6%) achieving zero treated bleeds 1 Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results fro...